ABCD² Score Calculator
Estimates 2-day, 7-day, and 90-day stroke risk following transient ischaemic attack (TIA). Scores range from 0 to 7, stratifying patients into low, moderate, and high-risk categories to guide the urgency of investigation and secondary prevention.
Calculate ABCD² Score
Enter the patient’s clinical features at the time of TIA presentation. Blood pressure should be the first recorded value in the emergency department or clinic. All five criteria are required to calculate the score.
The ABCD² score is a risk stratification tool — it does not diagnose TIA or determine treatment on its own. Current guidelines increasingly recommend urgent investigation and treatment for all TIA patients regardless of ABCD² score, as even low-risk scores do not exclude significant underlying pathology such as high-grade carotid stenosis or atrial fibrillation. The score should be used to guide the urgency of workup, not to decide whether workup is needed.
Understanding the ABCD² Score
The ABCD² score was developed in 2007 by Johnston and colleagues by combining two earlier TIA risk scores — the California score and the ABCD score — and adding diabetes mellitus as an additional predictor. The resulting seven-point scale was validated in large multi-centre cohorts and demonstrated improved predictive accuracy over its predecessors for short-term stroke risk following TIA.
The score captures five independent predictors of early stroke after TIA, each reflecting either the burden of underlying vascular disease (age, hypertension, diabetes) or the nature of the ischaemic event itself (clinical features, duration). The rationale is that TIAs with motor symptoms or prolonged duration are more likely to represent true ischaemic events with unstable vascular lesions, while brief non-motor episodes carry a lower — but not negligible — risk.
Scoring Criteria
A — Age ≥ 60 years: 1 point
B — BP ≥ 140/90 mmHg: 1 point
C — Clinical features:
Unilateral weakness: 2 points
Speech disturbance (no weakness): 1 point
Other: 0 points
D — Duration:
≥ 60 min: 2 points
10–59 min: 1 point
< 10 min: 0 points
D² — Diabetes: 1 point
Total range: 0–7
Worked Example
A 68-year-old woman presents with a 25-minute episode of slurred speech (no weakness) that has now resolved. Her BP is 158/94 mmHg. She has type 2 diabetes.
A — Age 68 (≥ 60): 1 pt
B — BP 158/94 (≥ 140/90): 1 pt
C — Speech, no weakness: 1 pt
D — 25 min (10–59): 1 pt
D² — Diabetes: 1 pt
Total: 5 (Moderate risk)
2-day stroke risk ≈ 4.1%
7-day risk ≈ 5.9%
The ABCD² score does not include imaging findings. High-grade ipsilateral carotid stenosis and acute DWI-positive lesions on MRI are powerful independent predictors of early stroke after TIA — stronger than several ABCD² components. This limitation led to the development of the ABCD²-I and ABCD³-I scores, which incorporate imaging, though these have not been as widely adopted in clinical practice.
Score Interpretation & Stroke Risk
The ABCD² score stratifies TIA patients into three risk categories based on pooled data from multiple validation cohorts. Risk estimates represent the probability of ischaemic stroke at 2-day, 7-day, and 90-day timepoints following the index TIA.
| ABCD² Score | Risk Category | 2-Day Stroke Risk | 7-Day Risk | 90-Day Risk |
|---|---|---|---|---|
| 0–3 | Low | ~1.0% | ~1.2% | ~3.1% |
| 4–5 | Moderate | ~4.1% | ~5.9% | ~9.8% |
| 6–7 | High | ~8.1% | ~11.7% | ~17.8% |
The highest risk period is the first 48 hours. Approximately half of strokes occurring within 90 days of a TIA happen within the first 2 days. This underpins the urgency of same-day investigation and treatment initiation for all confirmed or suspected TIA patients. The EXPRESS and SOS-TIA trials demonstrated that rapid-access TIA clinics with same-day assessment and treatment initiation reduced 90-day stroke risk by approximately 80% compared to standard outpatient referral.
Management Pathway by Risk Category
TIA Investigation & Differential Diagnosis
The ABCD² score guides urgency of investigation, but the investigation itself follows a standard pathway regardless of the score. A confirmed TIA diagnosis requires exclusion of stroke mimics and identification of the underlying vascular mechanism to target secondary prevention.
The core investigation pathway for suspected TIA includes brain imaging, vascular imaging, cardiac assessment, and laboratory studies. Brain MRI with DWI is the gold standard — approximately 30–50% of clinically diagnosed TIA patients have an acute DWI-positive lesion, indicating true ischaemia and a higher risk of subsequent stroke. CT brain is less sensitive but excludes haemorrhage and mass lesions.
Vascular imaging (carotid duplex ultrasound, CTA, or MRA) identifies ipsilateral carotid stenosis — a finding that dramatically increases stroke risk and is the strongest indication for urgent carotid endarterectomy or stenting. ECG and cardiac monitoring screen for atrial fibrillation, which changes the secondary prevention strategy from antiplatelet therapy to anticoagulation.
- Brain MRI with DWI: Ideally within 24 hours; DWI-positive TIA carries 2–3× higher stroke risk than DWI-negative
- Carotid duplex / CTA neck: Within 24 hours; ≥ 50% stenosis warrants surgical referral
- ECG + prolonged cardiac monitoring: At least 24-hour Holter; extended monitoring (7–30 days) for cryptogenic events
- Echocardiography: TTE or TOE for cardioembolic source, especially in younger patients or those without atherosclerotic risk factors
- Bloods: FBC, glucose, HbA1c, lipid panel, renal function, coagulation screen; thrombophilia screen in selected patients
Approximately 30–50% of patients referred with suspected TIA ultimately receive an alternative diagnosis. The ABCD² score was developed for patients with confirmed TIA — it has not been validated for undifferentiated patients and may misclassify mimics as high-risk. Common TIA mimics include migraine with aura, seizure with post-ictal deficit (Todd’s paresis), hypoglycaemia, vestibular disorders, and functional neurological disorder.
Migraine with aura is the most common mimic — it may cause transient focal symptoms (visual, sensory, or speech disturbance) that closely resemble TIA. Key differentiating features include gradual onset over minutes (vs abrupt onset in TIA), positive symptoms (tingling, visual sparkles) vs negative symptoms (numbness, visual loss), and the “march” of symptoms across body regions. A headache following the neurological symptoms supports migraine, though headache also occurs in up to 25% of genuine TIAs.
- Migraine with aura: Gradual onset, positive symptoms, symptoms march across regions, headache follows
- Seizure / post-ictal deficit: Positive motor symptoms (jerking), post-ictal confusion, Todd’s paresis resolves gradually
- Hypoglycaemia: Focal deficits possible at glucose < 3.0 mmol/L; check glucose in all patients
- Vestibular disorders: Isolated vertigo is rarely TIA — consider BPPV, vestibular neuritis, Ménière’s disease
- Functional neurological disorder: Positive signs of functional weakness (Hoover’s sign, drift without pronation)
- Syncope / presyncope: Global cerebral hypoperfusion, not focal ischaemia; no focal neurological symptoms
Two landmark trials — CHANCE (2013) and POINT (2018) — demonstrated that short-course dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel reduces early stroke risk after TIA and minor stroke compared to aspirin alone. The benefit is greatest in the first 21 days, after which the increased bleeding risk with DAPT begins to outweigh the ischaemic benefit.
The recommended DAPT protocol for non-cardioembolic TIA is: aspirin 300 mg loading dose plus clopidogrel 300 mg loading dose on day 1, followed by aspirin 75 mg plus clopidogrel 75 mg daily for 21 days, then clopidogrel 75 mg alone (or aspirin 75 mg alone) as long-term secondary prevention. This regimen reduced the 90-day stroke risk by approximately 25% relative to aspirin monotherapy. Importantly, DAPT is not indicated if anticoagulation is required (e.g., atrial fibrillation detected on workup).
- CHANCE trial: DAPT for 21 days reduced 90-day stroke from 11.7% to 8.2% vs aspirin alone (predominantly Chinese population)
- POINT trial: DAPT for 90 days reduced ischaemic events but increased major haemorrhage; 21 days appears optimal
- Timing: Greatest benefit when started within 12–24 hours of symptom onset
- Contraindication: Do not use DAPT if anticoagulation is indicated (e.g., AF, mechanical valve)
Symptomatic carotid stenosis (≥ 50% by NASCET criteria, or ≥ 70% by ECST criteria) on the side corresponding to the TIA symptoms is the strongest modifiable risk factor for early stroke after TIA. Carotid endarterectomy (CEA) or carotid artery stenting (CAS) in these patients reduces the 5-year stroke risk from approximately 26% to 9%.
The benefit of revascularisation is highly time-dependent — the number needed to treat (NNT) is approximately 5 when surgery is performed within 2 weeks of TIA, compared to NNT of 125 when delayed beyond 12 weeks. Current guidelines recommend that symptomatic carotid stenosis ≥ 50% should be referred for surgery or stenting within 14 days of the index event, and ideally within 7 days. Every day of delay reduces the benefit.
- ≥ 50% stenosis (NASCET): Benefit from CEA confirmed; greatest benefit at ≥ 70%
- Surgery within 14 days: NNT ~5; delay beyond 12 weeks reduces benefit by 80%
- Near-occlusion or string sign: May benefit less — specialist decision required
- Contralateral occlusion: Higher surgical risk but still net benefit if symptomatic
The “TIA 1-2-3” rule: All TIA patients need (1) immediate antiplatelet loading, (2) same-day or next-day specialist assessment with vascular imaging, and (3) complete secondary prevention optimisation within 72 hours — regardless of ABCD² score. The score guides urgency, not whether investigation is needed.
Special Populations & Considerations
The ABCD² score was derived and validated in predominantly elderly Caucasian populations. Its performance may vary in other demographics, and certain clinical scenarios require additional consideration beyond the score.
Imaging trumps the ABCD² score. A patient with ABCD² of 2 (low risk) but a high-grade ipsilateral carotid stenosis or DWI-positive lesion has a substantially higher stroke risk than their ABCD² score suggests. Similarly, an ABCD² of 6 with normal carotid arteries and negative DWI carries a lower absolute risk than the pooled data implies. Use the ABCD² as a starting point, then refine risk based on imaging findings.
Common Pitfalls & Limitations
The ABCD² score has well-documented limitations. Awareness of these ensures the tool is used appropriately within a comprehensive TIA assessment framework.
The most dangerous misuse of the ABCD² score is using a low score (0–3) to justify delayed investigation or discharge without workup. Studies have consistently demonstrated that a low ABCD² does not exclude high-risk pathology: approximately 20% of patients with ABCD² 0–3 have ipsilateral carotid stenosis ≥ 50%, and 15–20% have DWI-positive lesions on MRI. Furthermore, a meta-analysis by Defined et al. (2014) found the score has only modest discriminatory ability (C-statistic 0.60–0.70) — meaning it misclassifies a significant proportion of patients.
Clinical impact: A patient sent home from the emergency department with ABCD² of 2 and “outpatient neurology follow-up in 2 weeks” may have a 70% carotid stenosis that, if identified and treated within 48 hours, would have prevented a devastating stroke. Current guidelines from the AHA/ASA, NICE, and the European Stroke Organisation all recommend urgent investigation for all TIA patients, with ABCD² used only to prioritise the most urgent cases — never to defer investigation.
The ABCD² score was developed and validated in cohorts of patients with confirmed TIA. It has not been validated for undifferentiated patients presenting with transient neurological symptoms. Since 30–50% of suspected TIAs ultimately receive an alternative diagnosis, applying the ABCD² to all referrals inflates the apparent population at risk and may paradoxically worsen the score’s predictive value in clinical practice.
Clinical impact: A 62-year-old patient with a 20-minute episode of visual sparkles followed by headache (migraine with aura) would score ABCD² 2 (age 1 point, duration 1 point). Labelling this as “low-risk TIA” is doubly wrong — it applies a TIA risk score to a non-TIA diagnosis and may lead to unnecessary antiplatelet therapy while missing the correct diagnosis. The clinical diagnosis of TIA should be as rigorous as the scoring that follows it. If the diagnosis is uncertain, investigation should be driven by clinical suspicion, not the ABCD² score.
The stroke risk after TIA is front-loaded — roughly half of 90-day strokes occur within the first 48 hours, and the risk per day is highest in the first 24 hours. The ABCD² score provides static risk estimates (2-day, 7-day, 90-day) that do not account for when the patient presents within this timeline. A patient presenting 6 hours after TIA has a fundamentally different residual risk profile than one presenting at 5 days — yet both receive the same ABCD² score.
Clinical impact: The time from symptom onset to assessment should independently influence management urgency. A patient with ABCD² of 4 presenting 3 hours after TIA warrants more urgent management than the same score in a patient presenting at day 4 — most of the early risk has already passed by day 4. Always consider time-from-event alongside the ABCD² score when planning the urgency of investigation.
The original ABCD² risk estimates were derived from historical cohorts (pre-2007) where TIA management was less aggressive — many patients did not receive immediate antiplatelet therapy, urgent vascular imaging, or early secondary prevention optimisation. In the era of rapid-access TIA clinics, the EXPRESS and SOS-TIA studies showed that urgent treatment reduces 90-day stroke risk by approximately 80% (from ~10% to ~2%). This means the original ABCD² risk percentages likely overestimate current stroke risk when modern treatment protocols are followed.
Clinical impact: When counselling patients about their risk, it is appropriate to note that the published risk figures reflect historical, less intensive management. With modern urgent treatment protocols, the actual risk is substantially lower — but only if that treatment is actually initiated promptly. The overestimated risk is, paradoxically, useful in motivating adherence to the rapid investigation and treatment pathway.
The ABCD² score does not incorporate two of the most powerful predictors of stroke after TIA: ipsilateral carotid stenosis and acute DWI-positive brain lesion on MRI. Both independently double or triple the stroke risk beyond what the ABCD² score predicts. A comprehensive TIA assessment must include vascular imaging and, ideally, brain MRI with DWI — the ABCD² score is a clinical estimate pending these investigations, not a substitute for them.
Quick Reference Summary
| Criterion | Finding | Points |
|---|---|---|
| A — Age | ≥ 60 years | 1 |
| B — Blood Pressure | ≥ 140/90 mmHg | 1 |
| C — Clinical Features | Unilateral weakness | 2 |
| Speech disturbance (no weakness) | 1 | |
| D — Duration | ≥ 60 minutes | 2 |
| 10–59 minutes | 1 | |
| D² — Diabetes | Present | 1 |
The Golden Rule: Every TIA is a neurological emergency. The ABCD² score guides how urgently to investigate — not whether to investigate. Even ABCD² 0 requires vascular imaging, antiplatelet therapy, and secondary prevention. Treat TIA as a warning stroke: the next event may not be transient.
Disclaimer & References
For Educational Purposes Only. This calculator and the accompanying clinical information are intended as educational tools for healthcare professionals. They do not replace clinical judgement. Results should be interpreted in the full clinical context. Lab reference ranges vary by institution — verify with your own laboratory. Drug dosages should be confirmed against current prescribing information.
References
- Johnston SC, Rothwell PM, Nguyen-Huynh MN, et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet. 2007;369(9558):283-292. DOI: 10.1016/S0140-6736(07)60150-0
- Rothwell PM, Giles MF, Flossmann E, et al. A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack. Lancet. 2005;366(9479):29-36. DOI: 10.1016/S0140-6736(05)66702-5
- Giles MF, Rothwell PM. Systematic review and pooled analysis of published and unpublished validations of the ABCD and ABCD2 scores. Stroke. 2010;41(4):667-673. DOI: 10.1161/STROKEAHA.109.571174
- Rothwell PM, Giles MF, Chandratheva A, et al. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study). Lancet. 2007;370(9596):1432-1442. DOI: 10.1016/S0140-6736(07)61448-2
- Lavallée PC, Meseguer E, Abboud H, et al. A transient ischaemic attack clinic with round-the-clock access (SOS-TIA). Lancet Neurol. 2007;6(11):953-960. DOI: 10.1016/S1474-4422(07)70248-X
- Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (CHANCE). N Engl J Med. 2013;369(1):11-19. DOI: 10.1056/NEJMoa1215340
- Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA (POINT). N Engl J Med. 2018;379(3):215-225. DOI: 10.1056/NEJMoa1800410
- Barnett HJM, Taylor DW, Haynes RB, et al. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis (NASCET). N Engl J Med. 1991;325(7):445-453. DOI: 10.1056/NEJM199108153250701
- National Institute for Health and Care Excellence (NICE). Stroke and transient ischaemic attack in over 16s: diagnosis and initial management. Clinical guideline [NG128]. Updated 2022. Available at: nice.org.uk/guidance/ng128
- Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack (AHA/ASA). Stroke. 2021;52(7):e364-e467. DOI: 10.1161/STR.0000000000000375